【摘 要】
:
Introduction Mesenchymal stem cells (MSCs) contribute to the engraftment of transplanted hematopoietic stem cells (HSCs).MSCs also accelerate hematological recovery by secreting SDF-1 and enabling HSC
论文部分内容阅读
Introduction Mesenchymal stem cells (MSCs) contribute to the engraftment of transplanted hematopoietic stem cells (HSCs).MSCs also accelerate hematological recovery by secreting SDF-1 and enabling HSCs to enter the bone marrow (BM) via the SDF-1/CXCR4 axis.HOXB4 has been shown to stimulate HSC self-renewal.In this study, we examined whether SDF-1 and HOXB4 expression in MSCs co-transplanted with HSCs could synergistically improve hematopoietic recovery in irradiated mice.
其他文献
目的:观察天台乌药散联合α-受体阻滞剂治疗特发性慢性睾丸痛的疗效.方法:选取2015年9月-2016年12月门诊治疗的特发性慢性睾丸痛患者120例,随机分为治疗组60例和对照组60例.治疗组给予天台乌药散联合α-受体阻滞剂治疗,对照组给予α-受体阻滞剂口服.结果:治疗组有效率76.67%,对照组有效率56.67%,治疗组疗效优于对照组(P<0.05).结论:天台乌药散联合α-受体阻滞剂治疗特发性慢
目的 目前慢性再生障碍性贫血(CAA)的治疗主要有雄激素、免疫抑制剂、造血细胞输注和中医药等,但疗效不理想,且雄激素、免疫抑制剂的毒副反应大,研发安全有效的中药新药很有必要。本文首次观察中药新药派能达胶囊治疗CAA的疗效及其安全性,并探索有效的治疗方案。方法 36例诊断明确的CAA按病情分为3组:①派能达联合安雄减量组20例,入组病例均为雄激素160mg/日治疗2年以上者,采用派能达联合安雄减量组
目的 探讨骨髓涂片、骨髓活检、染色体显带分析、荧光原位杂交(fluorescence in site hybridization,FISH)及流式细胞学(flow cytometry,FCM)五项联合检验对骨髓增生异常综合征(myelodysplastic syndrome,MDS)的诊断价值.方法 回顾性分析2010年10月-2013年11月在我院经五联综合诊断技术联检,由WHO造血组织和淋巴系
目的 报告一例左肾旁结外NK/T细胞淋巴瘤隐匿起病的临床特点.方法 总结1例首发左肾旁鼻型结外NK/T细胞淋巴瘤患者的临床资料,并复习相关文献.结果 男性,60岁,病程3月,乏力伴反复发热3月余,间断鼻衄4天入院.最初因乏力伴间歇性中低度发热就诊,血常规提示白细胞减少,予以抗感染治疗后发热症状缓解,乏力持续,门诊随诊血常规相续出现血小板及血红蛋白下降;ALT、AST进行性缓慢升高,骨髓检查未见异常
目的 检测急性髓系白血病(acute myeloid leukemia,AML)患者骨髓中ID1 (inhibitors of differentiation 1)基因的表达并探讨其临床意义.方法 收集102例AML患者和28例健康者骨髓,应用实时定量PCR (real-time quantitative PCR,RQ-PCR)方法检测骨髓单个核细胞(bone marrow mononuclear
Background Gemtuzumab ozogamicin (GO) is a targeted antineoplastic agent comprised of a recombinant anti-CD33 humanized antibody linked to calicheamicin.Previous trials have showed conflicting results
Background and Objective There is no evidence that would definitively prove the superiority of IDA versus other anthracyclines in induction therapy of newly diagnosed acute myeloid leukemia (AML).We p
The right dose of daunorubicin (DNR) for the treatment of newly diagnosed acute myeloid leukemia (AML)is uncertain.Previous trials have shown conflicting results concerning the efficacy of high or low
Background and Objective Cyclosporine A (CsA) has been used as immunosuppressive therapy after allogeneic hematopoietic stem cell transplantation (HSCT) for about 30 years.Recently, Tacrolimus (FK506)
Background New evidence has questioned the role of high-dose cytarabine (HDAC) in consolidation therapy of acute myeloid leukemia (AML) in first complete remission (CR1).We performed a meta-analysis t